Clinical trial
HerpeVac Trial for Young Women
NCT00057330 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00057330 |
|---|---|
| Title | HerpeVac Trial for Young Women |
| Official title | A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Herpes Simplex Infection |
| Intervention type | Biological |
| Interventions | HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine |
| Enrollment | 8,323 |
| Start date | Jan 14, 2003 |
| Primary completion | Aug 22, 2009 |
| Completion | Aug 22, 2009 |
| First posted | Apr 1, 2003 |
| Last update posted | Aug 27, 2018 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: